EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam

Jane Knöchel iD, Vijender Panduga, Karin Nelander, Maria Heijer, Eva-Lotte Lindstedt, Hodan Ali, Malin Aurell, Helena Ödesjö, Pablo Forte, Kat Connolly, Hans Ericsson iD, Iain MacPhee

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16131 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Jane Knöchel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Midazolam, Drug Interactions, Cytochrome P-450 CYP3A, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Early clinical studies have indicated that the pharmacokinetics of Atuliflapon (AZD5718) are time and dose dependent. The reason(s) for these findings is(are) not fully understood, but pre‐clinical profiling suggests that time‐dependent CYP3A4 inhibition cannot be excluded. In clinical practice, Atuliflapon will be co‐administered with CYP3A4 substrates; thus, it is important to determine the impact of Atuliflapon on the pharmacokinetics (PK) of CYP3A4 substrates. The aim of this study was to evaluate the effect of Atuliflapon on the pharmacokinetics of a sensitive CYP3A4 substrate, midazolam, and to explore if the time‐/dose‐dependent effect seen after repeated dosing could be an effect of change in CYP3A4 activity.

Methods

Open‐label, fixed‐sequence study in healthy volunteers to assess the PK of midazolam alone and in combination with Atuliflapon. Fourteen healthy male subjects received single oral dose of midazolam 2 mg on days 1 and 7 and single oral doses of Atuliflapon (125 mg) from days 2 to 7. A physiologically based pharmacokinetic (PBPK) model was developed to assess this drug–drug interaction.

Results

Mean midazolam values of maximum plasma concentration (C max ) and area under the curve (AUC) to infinity were increased by 39% and 56%, respectively, when co‐administered with Atuliflapon vs. midazolam alone. The PBPK model predicted a 27% and 44% increase in AUC and a 23% and 35% increase in C max of midazolam following its co‐administrations with two predicted therapeutically relevant doses of Atuliflapon.

Conclusions

Atuliflapon is a weak inhibitor of CYP3A4; this was confirmed by the validated PBPK model. This weak inhibition is predicted to have a minor PK effect on CYP3A4 metabolized drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MidazolamDrug InteractionsCytochrome P-450 CYP3AModels, BiologicalHumansMaleAdultYoung AdultAdministration, OralArea Under CurveCytochrome P-450 CYP3A InhibitorsDose-Response Relationship, Drug

Stichwörter der Autor:innen

5‐lipoxygenase activating protein inhibitorPBPKdrug–drug interactionhealthy subjectsmidazolampharmacokinetics

Substanzen

MidazolamCytochrome P-450 CYP3ACYP3A4 protein, humanCytochrome P-450 CYP3A Inhibitors

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Patient safety, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • PAREXEL Early Phase Clinical Unit London, Northwick Park Hospital, Harrow, HA1 3UJ, UK.
  • Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Jane Knöchel, Hans Ericsson

Förderung

  • AstraZeneca

Zitieren

APA

Knöchel, J., Panduga, V., Nelander, K., Heijer, M., Lindstedt, E. L., Ali, H., Aurell, M., Ödesjö, H., Forte, P., Connolly, K., Ericsson, H., & MacPhee, I. (2024). A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16131

Vancouver

Knöchel J, Panduga V, Nelander K, Heijer M, Lindstedt EL, Ali H, et al. A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16131

BibTeX
@article{Knchel2024,
  author = {Knöchel, Jane and Panduga, Vijender and Nelander, Karin and Heijer, Maria and Lindstedt, Eva-Lotte and Ali, Hodan and Aurell, Malin and Ödesjö, Helena and Forte, Pablo and Connolly, Kat and Ericsson, Hans and MacPhee, Iain},
  title = {A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16131}
}
Kostenlos starten →